NCT04381884View on ClinicalTrials.gov

Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 18, 2020

Primary Completion Date

September 29, 2020

Study Completion Date

September 29, 2020

Conditions
COVID-19 Drug Treatment
Interventions
DRUG

IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily plus standard care. CONTROL arm will receive standard care.

Trial Locations (3)

Unknown

Hospital de Cuenca Alta, Cañuelas

"Centro de Educación Médica e Investigaciones Clínicas Norberto Quirno CEMIC", Buenos Aires

C1282AEN

Hospital de Infecciosas Francisco Javier Muñiz, Buenos Aires

Sponsors
All Listed Sponsors
collaborator

Universidad Nacional de Salta

OTHER

collaborator

Centro de Investigación Veterinaria Tandil CIVETAN

UNKNOWN

collaborator

Hospital de Pediatría Prof Dr. Juan P. Garrahan

UNKNOWN

collaborator

Universidad Nacional de Quilmes

UNKNOWN

lead

Laboratorio Elea Phoenix S.A.

INDUSTRY